CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants

References

• Daly AK. Molecular basis of polymorphic drug metabolism. J Mol Med 1995; 73:539–553.
   PubMed Web of Science ®Google Scholar
• Wilkinson GR. Drug metabolism and variability among patients in drug response. New Engl J Med 2005; 352:2211–2221.
   PubMed Web of Science ®Google Scholar
• CYP2D6 allele nomenclature. http://www.cypalleles.ki.se/cyp2d6.htm. (Last accessed on August 2014).
   Google Scholar
• Frank D, Jaehde U, Fuhr U. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol 2007; 63:321–333.
   PubMed Web of Science ®Google Scholar
• Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008; 83:234–242.
   PubMed Web of Science ®Google Scholar
• Clinical Pharmacogenetics Implementation Consortium (CPIC) for codeine, http://www.pharmgkb.org/guideline/PA166104996. (Last accessed on September 2014).
   Google Scholar
• Luminex 2D6v3 FDA approved kit, http://www.luminexcorp.com/Products/Assays/ClinicalDiagnostics/xTAGCYP2D6/. (Last accessed on September 2014).
   Google Scholar
• Dutch Pharmacogenetics Working Group Guidelines (DPWG) for codeine, http://www.pharmgkb.org/guideline/PA166104970. (Last accessed on September 2014).
   Google Scholar
• Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002; 3:229–243.
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. Pharmacogenetics of cytochrome p450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 2004; 25:193–200.
   PubMed Web of Science ®Google Scholar
• http://medicine.iupui.edu/clinpharm/ddis/main-table/. (Last accessed on August 2014).
   Google Scholar
• Law MY, Moody DE. Urinary excretion of amfetamine and 4’-hydroxyamphetamine by sprague dawley and dark agouti rats. Life Sci 1994; 54:1073–1079.
   PubMed Web of Science ®Google Scholar
• Maurer HH, Kraemer T, Springer D, Staack RF. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amfetamine (ecstasy), piperazine, and pyrrolidinophenone types: A synopsis. Ther Drug Monit 2004; 26:127–131.
   PubMed Web of Science ®Google Scholar
• Schwab M, Seyringer E, Brauer RB, Hellinger A, Griese EU. Fatal MDMA intoxication. Lancet 1999; 353:593–594.
   PubMed Web of Science ®Google Scholar
• Yang J, Jamei M, Heydari A, Yeo KR, de la Torre R, Farre M, et al.Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J Psychopharmacol 2006; 20:842–849.
   PubMed Web of Science ®Google Scholar
• Carmo H, Brulport M, Hermes M, Oesch F, Silva R, Ferreira LM, et al.Influence of CYP2D6 polymorphism on 3,4-methylenedioxymethamphetamine (’Ecstasy‘) cytotoxicity. Pharmacogenet Genomics 2006; 16:789–799.
   PubMed Web of Science ®Google Scholar
• Cherner M, Bousman C, Everall I, Barron D, Letendre S, Vaida F, et al.Cytochrome P450–2D6 extensive metabolizers are more vulnerable to methamfetamine-associated neurocognitive impairment: Preliminary findings. J Int Neuropsychol Soc 2010; 16:890–901.
   PubMed Web of Science ®Google Scholar
• Sutter ME, Gaedigk A, Albertson TE, Southard J, Owen KP, Mills LD, Diercks DB. Polymorphisms in CYP2D6 may predict methamfetamine related heart failure. Clin Toxicol 2013; 51:540–544.
   PubMed Web of Science ®Google Scholar
• Volpe DA, McMahon Tobin GA, Mellon RD, Katki AG, Parker RJ, Colatsky T, et al.Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs. Regul Toxicol Pharmacol 2011; 59:385–390.
   PubMed Web of Science ®Google Scholar
• Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. New Engl J Med 2004; 351:2827–2831.
   PubMed Web of Science ®Google Scholar
• Voronov P, Przybylo HJ, Jagannathan N. Apnea in a child after oral codeine: A genetic variant - an ultra-rapid metabolizer. Paediatr Anaesth 2007; 17:684–687.
   PubMed Web of Science ®Google Scholar
• Friedrichsdorf SJ, Nugent AP, Strobl AQ. Codeine-associated pediatric deaths despite using recommended dosing guidelines: three case reports. J Opioid Manag 2013; 9:151–155.
   PubMedGoogle Scholar
• Frost J, Helland A, Nordrum IS, Slordal L. Investigation of morphine and morphine glucuronide levels and cytochrome P450 isoenzyme 2D6 genotype in codeine-related deaths. Forensic Sci Int 2012; 220:6–11.
   PubMed Web of Science ®Google Scholar
• Ferreiros N, Dresen S, Hermanns-Clausen M, Auwaerter V, Thierauf A, Muller C, et al.Fatal and severe codeine intoxication in 3-year-old twins—interpretation of drug and metabolite concentrations. Int J Legal Med 2009; 123:387–394.
   PubMed Web of Science ®Google Scholar
• Shaw KD, Amstutz U, Jimenez-Mendez R, Ross CJ, Carleton BC. Suspected opioid overdose case resolved by CYP2D6 genotyping. Ther Drug Monit 2012; 34:121–123.
   PubMed Web of Science ®Google Scholar
• Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006; 368:704.
   PubMed Web of Science ®Google Scholar
• Madadi P, Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder JS, et al.Safety of codeine during breastfeeding: Fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Can Fam Physician 2007; 53:33–35.
   PubMed Web of Science ®Google Scholar
• Madadi P, Ross CJ, Hayden MR, Carleton BC, Gaedigk A, Leeder JS, Koren G. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: A case-control study. Clin Pharmacol Ther 2009; 85:31–35.
   PubMed Web of Science ®Google Scholar
• Willmann S, Edginton AN, Coboeken K, Ahr G, Lippert J. Risk to the breast-fed neonate from codeine treatment to the mother: A quantitative mechanistic modeling study. Clin Pharmacol Ther 2009; 86:634–643.
   PubMed Web of Science ®Google Scholar
• Juurlink DN, Gomes T, Guttmann A, Hellings C, Sivilotti ML, Harvey MA, Mamdani MM. Postpartum maternal codeine therapy and the risk of adverse neonatal outcomes: A retrospective cohort study. Clin Toxicol 2012; 50:390–395.
   Web of Science ®Google Scholar
• Madadi P, Moretti M, Djokanovic N, Bozzo P, Nulman I, Ito S, Koren G. Guidelines for maternal codeine use during breastfeeding. Can Fam Physician 2009; 55:1077–1078.
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Keulen JT, Bauer S, Roots I, Brockmoller J. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. J Clin Psychopharmacol 2008; 28:78–83.
   PubMed Web of Science ®Google Scholar
• Levo A, Koski A, Ojanpera I, Vuori E, Sajantila A. Post-mortem snp analysis of CYP2D6 gene reveals correlation between genotype and opioid drug (tramadol) metabolite ratios in blood. Forensic Sci Int 2003; 135:9–15.
   PubMed Web of Science ®Google Scholar
• Gleason PP, Frye RF, O’Toole T. Debilitating reaction following the initial dose of tramadol. Ann Pharmacother 1997; 31:1150–1152.
   PubMed Web of Science ®Google Scholar
• Stamer UM, Stuber F, Muders T, Musshoff F. Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. Anesth Analg 2008; 107:926–929.
   PubMed Web of Science ®Google Scholar
• Elkalioubie A, Allorge D, Robriquet L, Wiart JF, Garat A, Broly F, Fourrier F. Near-fatal tramadol cardiotoxicity in a CYP2D6 ultrarapid metabolizer. Eur J Clin Pharmacol 2011; 67:855–858.
   PubMed Web of Science ®Google Scholar
• Jannetto PJ, Wong SH, Gock SB, Laleli-Sahin E, Schur BC, Jentzen JM. Pharmacogenomics as molecular autopsy for postmortem forensic toxicology: genotyping cytochrome P450 2D6 for oxycodone cases. J Anal Toxicol 2002; 26:438–447.
   PubMed Web of Science ®Google Scholar
• Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, et al.Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br J Pharmacol 2010; 160:919–930.
   PubMed Web of Science ®Google Scholar
• Andreassen TN, Eftedal I, Klepstad P, Davies A, Bjordal K, Lundstrom S, et al.Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study . Eur J Clin Pharmacol 2012; 68:55–64.
   PubMed Web of Science ®Google Scholar
• Madadi P, Hildebrandt D, Gong IY, Schwarz UI, Ciszkowski C, Ross CJ, et al. Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions. Pediatrics 2010; 126:e986–989.
   PubMed Web of Science ®Google Scholar
• Xu BQ, Aasmundstad TA, Christophersen AS, Morland J, Bjorneboe A. Evidence for CYP2D1-mediated primary and secondary o-dealkylation of ethylmorphine and codeine in rat liver microsomes. Biochem Pharmacol 1997; 53:603–609.
   PubMed Web of Science ®Google Scholar
• Aasmundstad TA, Xu BQ, Johansson I, Ripel A, Bjorneboe A, Christophersen AS, et al.Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose. Br J Clin Pharmacol 1995; 39:611–620.
   PubMed Web of Science ®Google Scholar
• Xu BQ, Aasmundstad TA, Bjorneboe A, Christophersen AS, Morland J. Ethylmorphine o-deethylation in isolated rat hepatocytes. Involvement of codeine o-demethylation enzyme systems. Biochem Pharmacol 1995; 49:453–460.
   PubMed Web of Science ®Google Scholar
• Helland A, Isaksen CV, Slordal L. Death of a 10-month-old boy after exposure to ethylmorphine. J Forensic Sci 2010; 55:551–553.
   PubMed Web of Science ®Google Scholar
• Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, et al.Clinical pharmacogenetics implementation consortium (CPIC) guidelines for codeine therapy in the context of cytochrome p450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther 2012; 91:321–326.
   PubMed Web of Science ®Google Scholar
• Koski A, Sistonen J, Ojanpera I, Gergov M, Vuori E, Sajantila A. CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies. Forensic Sci Int 2006; 158:177–183.
   PubMed Web of Science ®Google Scholar
• Smith JC, Curry SC. Prolonged toxicity after amitriptyline overdose in a patient deficient in CYP2D6 activity. J Med Toxicol 2011; 7:220–223.
   PubMedGoogle Scholar
• Jornil J, Jensen KG, Larsen F, Linnet K. Risk assessment of accidental nortriptyline poisoning: The importance of cytochrome P450 for nortriptyline elimination investigated using a population-based pharmacokinetic simulator. Eur J Pharm Sci 2011; 44:265–272.
   PubMed Web of Science ®Google Scholar
• Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, et al.Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 2013; 93:402–408.
   PubMed Web of Science ®Google Scholar
• Koski A, Ojanpera I, Sistonen J, Vuori E, Sajantila A. A fatal doxepin poisoning associated with a defective CYP2D6 genotype. Am J Forensic Med Pathol 2007; 28:259–261.
   PubMed Web of Science ®Google Scholar
• Gex-Fabry M, Balant-Gorgia AE, Balant LP, Rudaz S, Veuthey JL, Bertschy G. Time course of clinical response to venlafaxine: relevance of plasma level and chirality. Eur J Clin Pharmacol 2004; 59:883–891.
   PubMed Web of Science ®Google Scholar
• McAlpine DE, Biernacka JM, Mrazek DA, O’Kane DJ, Stevens SR, Langman LJ, et al.Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine. Ther Drug Monit 2011; 33:14–20.
   PubMed Web of Science ®Google Scholar
• Lessard E, Yessine MA, Hamelin BA, O’Hara G, LeBlanc J, Turgeon J. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 1999; 9:435–443.
   PubMedGoogle Scholar
• Langford NJ, Martin U, Ruprah M, Ferner RE. Alternative venlafaxine kinetics in overdose. J Clin Pharm Ther 2002; 27:465–467.
   PubMed Web of Science ®Google Scholar
• Vinetti M, Haufroid V, Capron A, Classen JF, Marchandise S, Hantson P. Severe acute cardiomyopathy associated with venlafaxine overdose and possible role of CYP2D6 and CYP2C19 polymorphisms. Clin Toxicol 2011; 49:865–869.
   Web of Science ®Google Scholar
• Shams ME, Arneth B, Hiemke C, Dragicevic A, Muller MJ, Kaiser R, et al.CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 2006; 31:493–502.
   PubMed Web of Science ®Google Scholar
• Launiainen T, Rasanen I, Vuori E, Ojanpera I. Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions. Int J Legal Med 2011; 125:349–358.
   PubMed Web of Science ®Google Scholar
• Kingback M, Karlsson L, Zackrisson AL, Carlsson B, Josefsson M, Bengtsson F, et al.Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood. Forensic Sci Int 2012; 214:124–134.
   PubMed Web of Science ®Google Scholar
• Jornil J, Nielsen TS, Rosendal I, Ahlner J, Zackrisson AL, Boel LW, Brock B. A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine. Forensic Sci Int 2013; 226:e26–31.
   PubMed Web of Science ®Google Scholar
• Sallee FR, DeVane CL, Ferrell RE. Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. J Child Adolesc Psychopharmacol 2000; 10:27–34.
   PubMed Web of Science ®Google Scholar
• Sato A, Okura Y, Minagawa S, Ohno Y, Fujita S, Kondo D, et al. Life-threatening serotonin syndrome in a patient with chronic heart failure and CYP2D6*1/*5. Mayo Clin Proc 2004; 79:1444–1448.
   PubMed Web of Science ®Google Scholar
• Hyttel J, Bogeso KP, Perregaard J, Sanchez C. The pharmacological effect of citalopram residues in the (s)-(+)-enantiomer. J Neural Transm Gen Sect 1992; 88:157–160.
   PubMed Web of Science ®Google Scholar
• Carlsson B, Holmgren A, Ahlner J, Bengtsson F. Enantioselective analysis of citalopram and escitalopram in postmortem blood together with genotyping for CYP2D6 and CYP2C19. J Anal Toxicol 2009; 33:65–76.
   PubMed Web of Science ®Google Scholar
• Holmgren P, Carlsson B, Zackrisson AL, Lindblom B, Dahl ML, Scordo MG, et al.Enantioselective analysis of citalopram and its metabolites in postmortem blood and genotyping for CYP2D6 and CYP2C19. J Anal Toxicol 2004; 28:94–104.
   PubMed Web of Science ®Google Scholar